Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Strategic Projects - Group

McGill University

$325,100.00

Chemical biological approaches to new antifungals

EF 2007-08

Résumé
Infectious diseases are a growing problem for the Canadian health care system. Fungal infections represent a class of infectious diseases that are particularly hard to treat; fungal cells are very similar to human cells, so drugs that are capable of killing the disease-causing cells are often poisonous to humans as well. Fungal infections are seldom life threatening to healthy individuals. However, medical advances in cancer treatments and in organ transplantation, as well as the growing number of patients with AIDS, have created an increasing population of people that are at risk for serious fungal infections. Current treatments for fungal infections involve a small number of drugs, most of which work in similar ways. Some of these drugs are becoming less effective due to the development of resistance among the fungal pathogens, but the market for new drugs is not large enough to be attractive to large pharmaceutical companies. We propose to identify new chemicals that work together with a current drug called fluconazole. Fluconazole alone can block the growth of fungal cells; we hope to identify compounds that will. In combination with fluconazole, kill the disease-causing organisms. This reduces the chance of the fungal cells developing resistance, and makes the treatment more effective. We have already identified fungal cells that have missing genes that make them very sensitive to fluconazole; we will now identify compounds that inactivate the same cellular functions that are made defective by the missing genes. These compounds will be identified through direct screens, and also by genetic strategies that turn the previously non-essential functions into essential ones. Large collections of chemicals will be tested to find these new compounds using high-throughput screening. Ultimately, compounds that are identified as killing the fungal cells on plates will be tested in animal models to see if they enhance the ability of fluconazole to cure infections. This general strategy of combining drugs has proven useful in the fight against bacterial infections; the current proposal provides a strategy to find similar successful combinations in the fight against fungal disease.
Programme
Strategic Projects - Group
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
322252-2005
Name nom
Thomas, David
Department département
Biochemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2005
Award amount
325100
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1001
Committee name en
Strategic Projects Selection Panel - Biosciences A
Committee name fr
Comité de sélection des projets stratégiques - biosciences A
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5000
Research subject group en
Genetics
Research subject group fr
Génétique
Research subject en
Genetics
Research subject fr
Génétique
Partie
3
Nb partie
3
Application title
Chemical biological approaches to new antifungals
Keyword
NA
Application summary
Infectious diseases are a growing problem for the Canadian health care system. Fungal infections represent a class of infectious diseases that are particularly hard to treat; fungal cells are very similar to human cells, so drugs that are capable of killing the disease-causing cells are often poisonous to humans as well. Fungal infections are seldom life threatening to healthy individuals. However, medical advances in cancer treatments and in organ transplantation, as well as the growing number of patients with AIDS, have created an increasing population of people that are at risk for serious fungal infections. Current treatments for fungal infections involve a small number of drugs, most of which work in similar ways. Some of these drugs are becoming less effective due to the development of resistance among the fungal pathogens, but the market for new drugs is not large enough to be attractive to large pharmaceutical companies. We propose to identify new chemicals that work together with a current drug called fluconazole. Fluconazole alone can block the growth of fungal cells; we hope to identify compounds that will. In combination with fluconazole, kill the disease-causing organisms. This reduces the chance of the fungal cells developing resistance, and makes the treatment more effective. We have already identified fungal cells that have missing genes that make them very sensitive to fluconazole; we will now identify compounds that inactivate the same cellular functions that are made defective by the missing genes. These compounds will be identified through direct screens, and also by genetic strategies that turn the previously non-essential functions into essential ones. Large collections of chemicals will be tested to find these new compounds using high-throughput screening. Ultimately, compounds that are identified as killing the fungal cells on plates will be tested in animal models to see if they enhance the ability of fluconazole to cure infections. This general strategy of combining drugs has proven useful in the fight against bacterial infections; the current proposal provides a strategy to find similar successful combinations in the fight against fungal disease.